Oncology

graphic image of a cube with an arrow nailing the bullseye
Biotech

ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC

The companies plan to submit the EGFR tyrosine kinase inhibitor for an FDA approval during the second half of this year.
Gabrielle Masson May 22, 2025 5:00pm
BioNTech

BioNTech makes £1B commitment to expand UK research, build HQ

May 20, 2025 11:15am
reshuffle pipeline target reorganize shift change

Recursion streamlines pipeline following merger with Exscientia

May 5, 2025 11:00am
Caribou antlers sitting on ground with mountains in background

Caribou cuts 32% of staff, further purges cell therapy pipeline

Apr 24, 2025 9:55pm
Mosaic pattern collage

Mosaic licenses 2 clinical stage tumor drugs from Otsuka's Astex

Apr 24, 2025 10:00am
cellos without players

Bayer boosts precision oncology efforts with multiyear AI deal

Apr 23, 2025 12:55pm
More News

Tempus AI in line for $200M from AstraZeneca cancer model deal

Apr 23, 2025 9:01am

Boehringer slots synthetic lethal program into oncology pipeline

Apr 23, 2025 7:45am

Tempest lays off 80% of workforce to ride out cash crunch

Apr 21, 2025 8:20am

Flatiron Health, Massive Bio forge patient recruitment pact

Apr 9, 2025 12:47pm